Given that SHP-1 dephosphorylates PKM2Y105 reversing its nucleus-dependent proliferative activity, the discovery of small molecules targeting SHP-1 may be a promising strategy through which to inhibit PKM2-related nonglycolytic function and the Warburg effect for cancer treatment. The gene discussed is PKM; the disease is cancer.